To assess the prevalence of CYP 3A5 genomic variances and their impact on tacrolimus
(TAC) dosing requirements among kidney transplant recipients in eastern North Carolina …

It is currently not clear whether the concentration‐time curves of the immunosuppressants
differ with respect to the CYP3A5, MDR1, or MRP2 genotype in dose‐adapted stable kidney …

Cyclosporine A and tacrolimus (Tac) are inmunosuppresive drugs with a narrow therapeutic
range. Underdosing is associated with organ rejection, whereas overdosing could result in …

Aims Tacrolimus (TAC) is one of the most successful immunosuppressive drugs in
transplantation. Its pharmacokinetics (PK) and pharmacogenetics (PG) have been …

Tacrolimus is a widely used immunosuppressive drug for preventing the rejection of solid
organ transplants. The efficacy of tacrolimus shows considerable variability, which might be …

Background Polymorphisms in genes encoding transport proteins and metabolizing
enzymes involved in tacrolimus (TAC) disposition may be important sources of individual …

Background Tacrolimus is a common immunosuppressive for transplantation. The enzyme
encoded by the CYP3A5 gene can regulate the metabolism of tacrolimus, and the …

The tacrolimus is metabolized primarily by CYP3A5, a member of the single nucleotide
polymorphism family. It shows cytochrome P450 (SNP) in intron 3, which consists of a …

Genetic polymorphisms in biotransformation enzyme CYP3A5 (6986G> A, CYP3A5* 3;
14690A> G, CYP3A5* 6) and drug transporter ABCB1 (1236C> T; 2677G> T/A; 3435C> T) …

Background: Tacrolimus is established as immunosuppressant after kidney transplantation.
Polymorphism of the cytochrome P450 3A5 (CYP3A5) gene contributes significantly to …